Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2-advanced gastric or gastroesophageal junction cancer (GC/GEJC)
Author
Lonardi, Sara
Moehler, Markus H.
Dvorkin, Mikhail
Ozguroglu, Mustafa
Ryu, Min-hee
Muntean, Alina Simona
Nechaeva, Marina
Bragagnoli, Arinilda Silva Campos
Coskun, Hasan Senol
Gracian, Antonio Cubillo
Takano, Toshimi
Wong, Rachel
Safran, Howard
Vaccaro, Gina M.
Boku, Narikazu
Conti, Ilaria
Hong, Janet
Xiong, Huiling
Taieb, Julien
Bang, Yung-Jue
Metadata
Show full item recordCollections
- Bildiri [64839]